Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

Sarfez Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Body Weight Changes

Treatments: Drug: CHF Patients: Furosemide 40 mg; Drug: CHF Patients: ER Torsemide 40 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03509545

CLCD-075-17

Details and patient eligibility

About

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Full description

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Enrollment: 20 patients

Sex: Male

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.

Exclusion criteria

• Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

CHF Patients: ER Torsemide 40 mg

Experimental group

Description:

CHF patients will be given 40 mg ER Torsemide

Treatment:

Drug: CHF Patients: ER Torsemide 40 mg

CHF Patients: Furosemide 40 mg

Active Comparator group

Description:

CHF patients are on 40 mg of Furosemide

Treatment:

Drug: CHF Patients: Furosemide 40 mg